candesartan has been researched along with Cerebral Infarction in 8 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Cerebral Infarction: The formation of an area of NECROSIS in the CEREBRUM caused by an insufficiency of arterial or venous blood flow. Infarcts of the cerebrum are generally classified by hemisphere (i.e., left vs. right), lobe (e.g., frontal lobe infarction), arterial distribution (e.g., INFARCTION, ANTERIOR CEREBRAL ARTERY), and etiology (e.g., embolic infarction).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Candesartan treatment alleviated matrisome protein accumulation and normalized the vascular distensibility and cerebral blood flow." | 1.62 | Candesartan prevents arteriopathy progression in cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy model. ( Ando, S; Fujita, N; Fukunaga, M; Hasegawa, M; Hatano, Y; Hirokawa, S; Igarashi, H; Ihara, M; Kakita, A; Kametani, F; Kanazawa, M; Kato, T; Kawashima, Y; Kawata, H; Koyama, A; Manabe, RI; Matsumoto, M; Murayama, S; Nishizawa, M; Nozaki, H; Onodera, O; Saito, R; Saito, S; Sato, T; Sekine, Y; Sugai, A; Sugie, A; Toyoshima, Y; Tsuji, S; Uemura, M, 2021) |
| "A 31-year-old woman developed bilateral posterior ischemic optic neuropathy and infarctions of the cerebral arterial border zones and spinal cord after correction of malignant hypertension." | 1.35 | Simultaneous posterior ischemic optic neuropathy, cerebral border zone infarction, and spinal cord infarction after correction of malignant hypertension. ( An, SJ; Choi, JH; Choi, KD; Kim, HJ; Kim, JS; Lee, JE, 2008) |
| "However, the endothelin-1 (ET-1)-induced middle cerebral artery occlusion (MCAO) model of cerebral ischaemia is thought to more closely mimic the temporal events of an embolic stroke." | 1.35 | Candesartan pretreatment is cerebroprotective in a rat model of endothelin-1-induced middle cerebral artery occlusion. ( Katovich, MJ; Mecca, AP; O'Connor, TE; Sumners, C, 2009) |
| "pretreatment with candesartan, 0." | 1.32 | Chronic pretreatment with candesartan improves recovery from focal cerebral ischaemia in rats. ( Blume, A; Culman, J; Gohlke, P; Groth, W; Unger, T, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (87.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Kato, T | 1 |
| Manabe, RI | 1 |
| Igarashi, H | 1 |
| Kametani, F | 1 |
| Hirokawa, S | 1 |
| Sekine, Y | 1 |
| Fujita, N | 1 |
| Saito, S | 1 |
| Kawashima, Y | 1 |
| Hatano, Y | 1 |
| Ando, S | 1 |
| Nozaki, H | 1 |
| Sugai, A | 1 |
| Uemura, M | 1 |
| Fukunaga, M | 1 |
| Sato, T | 2 |
| Koyama, A | 1 |
| Saito, R | 1 |
| Sugie, A | 1 |
| Toyoshima, Y | 1 |
| Kawata, H | 1 |
| Murayama, S | 1 |
| Matsumoto, M | 1 |
| Kakita, A | 1 |
| Hasegawa, M | 1 |
| Ihara, M | 1 |
| Kanazawa, M | 1 |
| Nishizawa, M | 1 |
| Tsuji, S | 1 |
| Onodera, O | 1 |
| Choi, JH | 1 |
| Choi, KD | 1 |
| Kim, JS | 1 |
| Kim, HJ | 1 |
| Lee, JE | 1 |
| An, SJ | 1 |
| Mecca, AP | 1 |
| O'Connor, TE | 1 |
| Katovich, MJ | 1 |
| Sumners, C | 1 |
| Yamakawa, H | 1 |
| Jezova, M | 1 |
| Ando, H | 1 |
| Saavedra, JM | 1 |
| Groth, W | 1 |
| Blume, A | 1 |
| Gohlke, P | 1 |
| Unger, T | 1 |
| Culman, J | 1 |
| Fukui, T | 1 |
| Rahman, M | 1 |
| Hayashi, K | 1 |
| Takeda, K | 1 |
| Higaki, J | 1 |
| Fukushima, M | 1 |
| Sakamoto, J | 1 |
| Morita, S | 1 |
| Ogihara, T | 1 |
| Fukiyama, K | 1 |
| Fujishima, M | 1 |
| Saruta, T | 1 |
| Schrader, J | 1 |
| Diener, HC | 1 |
| Lüders, S | 1 |
| Engelhorn, T | 1 |
| Doerfler, A | 1 |
| Heusch, G | 1 |
| Schulz, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-Risk Hypertensive Patients[NCT00125463] | Phase 3 | 3,200 participants | Interventional | 2001-09-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for candesartan and Cerebral Infarction
| Article | Year |
|---|---|
Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cerebral Hemorrhage; Cerebral Infarctio | 2003 |
7 other studies available for candesartan and Cerebral Infarction
| Article | Year |
|---|---|
Candesartan prevents arteriopathy progression in cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy model.
Topics: ADAMTS Proteins; Alopecia; Animals; Benzimidazoles; Biphenyl Compounds; Cerebral Infarction; Cerebro | 2021 |
Simultaneous posterior ischemic optic neuropathy, cerebral border zone infarction, and spinal cord infarction after correction of malignant hypertension.
Topics: Adult; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Brain; Brain Stem Infarctions; C | 2008 |
Candesartan pretreatment is cerebroprotective in a rat model of endothelin-1-induced middle cerebral artery occlusion.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Brain Ischemia | 2009 |
Normalization of endothelial and inducible nitric oxide synthase expression in brain microvessels of spontaneously hypertensive rats by angiotensin II AT1 receptor inhibition.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Arterial Occlusive Diseases; Ben | 2003 |
Chronic pretreatment with candesartan improves recovery from focal cerebral ischaemia in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2003 |
[Treating high blood pressure in acute stroke].
Topics: Acute Disease; Adrenergic alpha-Agonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Conve | 2004 |
Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the HMG-CoA reductase inhibitor rosuvastatin and their combination. An experimental study in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Brain; Cerebra | 2006 |